Cite

HARVARD Citation

    Moore, D. et al. (2018). Cost savings analysis and toxicity audit of a bevacizumab dose rounding policy at a community cancer center. Journal of oncology pharmacy practice. pp. 42-46. [Online]. 
  
Back to record